Welcome to our dedicated page for RESMED SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESMED's regulatory disclosures and financial reporting.
ResMed Inc. reported board and auditor changes. On August 13, 2026, the Audit Committee dismissed KPMG as independent registered public accounting firm and selected PricewaterhouseCoopers LLP (PwC), subject to completion of PwC’s standard client acceptance procedures, for the fiscal year ending June 30, 2027. KPMG’s audit reports for the fiscal years ended June 30, 2026 and 2025 contained no adverse opinions, disclaimers, or qualifications, and ResMed states there were no disagreements or reportable events with KPMG. The company also states it did not consult PwC on accounting or auditing matters during these periods. Director Ronald Taylor informed the Board he will not stand for election at the 2026 annual meeting, expected on November 18, 2026, and will retire at that time. The Board approved Carol Burt as lead director effective November 15, 2026, and these governance changes were announced in a press release furnished as an exhibit.
ResMed Inc. is a Delaware-based global leader in digital health and cloud‑connected medical devices focused on sleep and breathing disorders and residential care software. Operations are organized into two segments: Sleep and Breathing Health, and Residential Care Software.
The company sells CPAP, APAP, bilevel and ventilation devices, masks, diagnostics, and AI‑enabled software such as AirView and myAir in more than 140 countries, employing approximately 11,370 people. Devices generated about 51% of net revenue in fiscal 2026, masks and diagnostics about 37%, and Residential Care Software about 12%.
In 2025 ResMed acquired VirtuOx, an independent diagnostic testing facility, expanding home‑based diagnostics. In June 2026 it acquired Noctrix Health, adding an FDA De Novo classified wearable device for restless legs syndrome. On June 30, 2026, ResMed entered a definitive agreement to sell its MatrixCare business for $490 million in cash, sharpening focus on core sleep, breathing, and connected home‑based healthcare.
ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 options for ResMed Common Stock at an exercise price of $146.34 per share and acquired the same number of shares on August 7, 2026. He then sold 4,991 shares of ResMed Common Stock at a weighted average price of $205.6895 per share, with individual trades ranging from $202.410 to $204.160. The option exercise and related sale were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the option transaction, he held 14,975 ResMed Common Stock options and had an indirect holding of 2,090 ResMed Common Stock shares through the Lisette and Michael Farrell Family Trust.
AustralianSuper Pty Ltd reported a significant ownership position in ResMed Inc. The investor beneficially owns 8,276,381 ordinary shares of ResMed Inc., representing 5.71% of the class as of June 30, 2026. AustralianSuper has sole power to vote and dispose of all 8,276,381 shares, with no shared voting or dispositive power reported. The filing identifies AustralianSuper as an Australian entity operating as an employee benefit plan and/or investment company, disclosing this stake on a passive Schedule 13G basis.
ResMed shareholder Michael Farrell lists a proposed sale of 4,991 shares of common stock, to be sold for cash on 08/07/2026 through Fidelity Brokerage Services LLC on the NYSE, in connection with a stock option exercise.
The disclosure also lists prior sales of 4,991 shares of common stock on each of 05/07/2026, 06/08/2026, and 07/07/2026, with aggregate sale prices of $1,037,232.61, $968,064.34, and $1,090,770.57, respectively.
ResMed Inc. reported higher sales and earnings for the quarter and fiscal year ended June 30, 2026, and announced a larger dividend. For the fourth quarter, revenue was $1,464 million, up 9% from $1,348 million. GAAP diluted EPS was $2.64 versus $2.58, while non-GAAP diluted EPS rose to $2.95 from $2.55. GAAP gross margin declined to 58.8% from 60.8%, reflecting items such as $41.9 million of Astral field safety notification expenses, but non-GAAP gross margin improved to 62.3% from 61.4%.
For fiscal 2026, revenue reached $5,653 million, a 10% increase year over year. GAAP diluted EPS was $10.43 versus $9.51, and non-GAAP diluted EPS increased to $11.17 from $9.55, as operating margin expanded to 33.4% and non-GAAP operating margin to 36.1%. Operating cash flow for the year was $1,806 million. The board declared a quarterly cash dividend of $0.66 per share, a 10% increase, with a record date of August 20, 2026 and payment on September 24, 2026; holders of CHESS Depositary Interests on the ASX will receive an equivalent amount based on the 10:1 CDI-to-share ratio.
ResMed Inc. director Peter C. Farrell reported selling 8,000 shares of ResMed Common Stock on 2026-08-05 at $225.00 per share in an open-market or private transaction. The sale was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
After this transaction, Farrell directly holds 52,773 shares of ResMed Common Stock.
A Form 144 related to RMD reports a proposed sale of up to 8,000 common shares through Merrill Lynch on the NYSE, with an indicated value of $1,799,642.92. Shares outstanding are listed as 145,056,384. The filing also lists multiple stock options for Peter C Farrell with various grant and exercise dates and share amounts.
ResMed Inc Chairman and CEO Michael J. Farrell exercised stock options and sold shares in a pre-planned transaction. He exercised options for 4,991 shares of ResMed common stock at an exercise price of $146.3400 per share, then sold 4,991 shares in open-market trades at a weighted average price of $218.5475 per share.
The sales were executed in multiple trades at prices ranging from $216.772 to $219.700 under a Rule 10b5-1 plan adopted on October 31, 2024. Following the transactions, Farrell directly holds 466,223 shares of ResMed common stock and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, and 19,966 stock options remain outstanding.
ResMed is reshaping its portfolio by agreeing to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, with closing expected in the first quarter of fiscal 2027, subject to regulatory approvals and customary conditions. MatrixCare generated about $220 million of revenue and $55 million of non-GAAP operating profit in fiscal 2026.
ResMed plans to use net proceeds to return capital to shareholders, including via an accelerated share repurchase program, and for general corporate purposes. Transition services agreements are expected to largely offset first-year stranded costs. The company also notes its Noctrix acquisition should add roughly $30 million of revenue in fiscal 2027 but reduce non-GAAP diluted EPS by about $0.20, while it reiterates its fiscal 2026 outlook and targets high single-digit revenue growth with operating leverage in its Residential Care Software segment in fiscal 2027.